The study analyzed that the dry eye syndrome therapeutics pipeline comprises approximately 50 drug candidates, of which 11 drug candidates are in Phase III stage of development, 16 drug candidates are in Phase II stage of development, five drug candidates are in Phase I stage, while 17 drug candidates are in Pre-Clinical stage and one drug candidate in the Discovery stage of development. Dry eye syndrome is also known as keratoconjunctivitis sicca or keratitis sicca. The disease is caused by a chronic lack of sufficient moisture and lubrication on the ocular surface of the eye. Some of the major consequences of dry eyes include constant eye irritation, significant inflammation and scarring of the front surface of the eye.
Explore Report Description at: https://www.psmarketresearch.com/market-analysis/dry-eye-syndrome-therapeutics-pipeline-analysis
Insights on pipeline segments
According to the research findings, around 78.0% drug candidates of dry eye syndrome pipeline are being developed to be administered by topical route and 4.0% are to be administered by other routes, that include oral and intracanalicular. Route of administration of around 18.0% drug candidates of dry eye syndrome pipeline has not been not disclosed.
Natural Sources are being used for the development of drugs in the Dry Eye Syndrome Therapeutics Pipeline
The research also found that various companies use natural sources for the development of dry eye syndrome therapeutics pipeline. MC2 Therapeutics is developing a drug by the name, MC203, in Phase II stage of development as a topical agent using ciclosporin, obtained from a natural source, for the treatment of dry eye syndrome. RegeneRx Biopharmaceuticals, Inc. is under the process of developing thymosin beta-4, which is in Phase III stage of development as an inhibitor of nuclear factor kappa-B activation, using a natural source, for the treatment of dry eye syndrome.
Many companies are involved in the development of drugs for the dry eye syndrome therapeutics pipeline, with their products in different phases. Allergan Plc has two drug candidates in the Phase III stage of development. Companies such as Mitotech, SA, RegeneRx Biopharmaceuticals, Inc. and Sylentis, S.A.U. have their drug candidates in the Phase II stage of development. Novaliq GmbH is in the process of developing four drug candidates of which one is in the Phase III stage of development, one is in the Phase II stage of development and two are in the Pre-Clinical stage of development. Nemus Bioscience, Inc. has one drug candidate in the Discovery stage of development.
Some of the other key players developing drugs for the treatment of dry eye syndrome include Ocular Therapeutix, Inc., LTT Bio-Pharma, HanAll BioPharma Co., Ltd., Laboratoires Thea, Avizorex Pharma, S.L., Sylentis, S.A.U., RegeneRx Biopharmaceuticals, Inc., Mitotech, SA, Seikagaku Corporation, KPI Therapeutics Inc. and Xigen SA.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-Free: +1-888-778-7886 (USA/Canada)